Calretinin as a blood-based biomarker for mesothelioma

BMC Cancer

Table 2 Performance of calretinin and mesothelin for the detection of malignant mesothelioma in pooled data (group 2: 80 MM and 75 controls; group 3: 36 MM and 72 controls)

Biomarker	False-positive rate	Cutoff	True positive	True negative	False positive	False negative	Sensitivity	Specificity
Calretinin^a[ng/mL]	0.01	1.07	60	145	2	56	0.52	0.99
Calretinin^a[ng/mL]	0.02	0.83	70	144	3	46	0.60	0.98
	0.03	0.68	78	142	5	38	0.67	0.97
	0.04	0.63	79	141	6	37	0.68	0.96
	0.05	0.58	82	139	8	34	0.71	0.95
Mesothelin^b[nmol/L]	0.01	2.32	71	145	2	45	0.61	0.99
Mesothelin^b[nmol/L]	0.02	2.31	71	144	3	45	0.61	0.98
	0.03	2.15	76	142	5	40	0.66	0.97
	0.04	2.02	78	141	6	38	0.67	0.96
	0.05	1.99	80	139	8	36	0.69	0.95

^aPerformance measures based on nonparametric ROC curve in Fig. 4a (AUC = 0.86, 95% CI = 0.82–0.91)
^bPerformance measures based on nonparametric ROC curve in Fig. 4b (AUC = 0.89, 95% CI = 0.85–0.93)

ISSN: 1471-2407